B
Bo Lu
Researcher at Ohio State University
Publications - 390
Citations - 24905
Bo Lu is an academic researcher from Ohio State University. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 58, co-authored 353 publications receiving 21823 citations. Previous affiliations of Bo Lu include Wuhan University of Technology & Wuhan University.
Papers
More filters
Journal ArticleDOI
The complete mitogenome of the Atlantic hydrothermal vent shrimp Rimicaris exoculata Williams & Rona 1986 (Crustacea: Decapoda: Alvinocarididae).
TL;DR: Determination of the R. exoculata mitogenome can help to resolve the consensus Decapoda tree of life and provides more genetic information available for phylogenetics as well as population genetics on this extensively studied species from hydrothermal vents.
Journal ArticleDOI
Impact of Sarcopenia on Survival in Patients With Early-Stage Lung Cancer Treated With Stereotactic Body Radiation Therapy.
TL;DR: A retrospective analysis of consecutive patients treated with SBRT from 2013 to 2019 found that sarcopenia was not associated with OS, LFS, or DFS, and increasing BMI was associated with improved OS.
Journal ArticleDOI
Plasminogen activator inhibitor-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer.
Hongyu Li,Eric T. Shinohara,Qiuyin Cai,Heidi Chen,Regina Courtney,Carolyn Cao,Z. Wang,M. Teng,Wei Zheng,Bo Lu +9 more
TL;DR: PAI-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer, and the genotype had no statistically significant relationship with other prognostic factors.
Journal ArticleDOI
A patient alignment solution for lung SBRT setups based on a deformable registration technique
Bo Lu,K Mittauer,Jonathan G. Li,Sanjiv Samant,Roi Dagan,Paul Okunieff,Darren Kahler,Chihray Liu +7 more
TL;DR: The CTC method can generate optimal dose coverage to tumors with much better consistency compared with either the G or B method, and it is especially useful when the tumor position varies greatly from its position on the original CT, relative to the rib cage.
Journal ArticleDOI
A Pilot Study of Radiation Therapy in Combination With Pembrolizumab in Patients With Metastatic Renal Cell Cancer.
Jianqing Lin,Andrew Song,Jean H. Hoffman-Censits,Benjamin E. Leiby,Madalina Tuluc,Colette M. Shaw,Larry Harshyne,Rhonda B. Kean,Voichita Bar-Ad,Robert B. Den,Mark D. Hurwitz,Jennifer Louie,Sherin Philipose,Sandeep Deshmukh,Jennifer Johnson,Adam P. Dicker,Douglas C. Hooper,William Kevin Kelly,Bo Lu +18 more
TL;DR: Combining RT with pembrolizumab in pretreated mRCC is well-tolerated and appears to have comparable efficacy with single-agent nivolumab.